

April 18, 2008

Archimica sells Puerto Rico facility and completes turnaround

Sulzbach, Germany. Archimica has signed and completed a transaction to sell its 5-Fluorouracil production facility at Humacao, Puerto Rico, to a subsidiary of Teva Pharmaceutical Industries Ltd (Nasdaq: TEVA). Financial details of the transaction were not disclosed. The sale of the single-product Humacao facility is an important step in the company's strategic focus on multipurpose facilities for technologically differentiated building blocks and API. Archimica also announced that its turnaround project is complete.

Restructuring activities began during the fourth quarter of 2006 and have included product complexity and cost rationalisation activities at Archimica's Italian, US and UK businesses. These activities have occurred in parallel with significant investment in core technologies and business systems across all sites.

James Harrison, CEO of Archimica, stated: "Archimica's strategy for the introduction of new manufacturing projects focuses on close cooperation with innovative pharmaceutical companies on phase II and phase III clinical trial material manufacturing and with generic pharmaceutical companies on new generic drug development. This strategy requires a flexible and multipurpose pilot and production plant network coupled with our strong technology portfolio. As a single-product site, the Humacao facility became a non-core operation, and we are pleased to complete this transaction with Teva. We wish the Puerto Rico team success under their new ownership.

Completion of Archimica's turnaround activities positions Archimica as a lean pharmaceutical fine chemicals manufacturer with flexible, high-tech pilot and large-scale manufacturing operations in Western Europe and the US and a growing R&D and technical marketing team. We look forward to continuing to build our key customer relationships."

Archimica – Strong. Steady. Focused on Pharmaceuticals.

Archimica is a privately held pharmaceutical fine chemicals company. Archimica combines world-scale chemical manufacturing experience with a history of pharmaceutical commercialization that stretches back over 40 years. With seven production sites in Italy, France, Germany, UK and the US and 2007 sales of approximately 200 Mio US\$, the company is particularly focused on custom synthesis of high-tech building blocks, intermediates and APIs in close cooperation with its clients. Archimica's core technologies are cryogenic reactions especially for boronic acids (8 full-scale – 100 °C production lines up to 12.000 L), Pd-catalyzed chemistries for biaryls and C,X-couplings, hydrogenations up to 80 bar, phosgenation with triphosgene, heterocyclic products, enzymatic chemistries, nitrations and aseptic filtration for bulk steriles.